PMID- 17087808
OWN - NLM
STAT- MEDLINE
DCOM- 20070321
LR  - 20171016
IS  - 1743-6095 (Print)
IS  - 1743-6095 (Linking)
VI  - 4
IP  - 1
DP  - 2007 Jan
TI  - Patients responding to phosphodiesterase type 5 inhibitor therapy: what do their 
      sexual partners know?
PG  - 162-165
LID - S1743-6095(15)31502-2 [pii]
LID - 10.1111/j.1743-6109.2006.00346.x [doi]
AB  - INTRODUCTION: Phosphodiesterase type 5 (PDE5) inhibitors are an efficacious 
      therapy in men with erectile dysfunction (ED). There are only a few studies that 
      also focus on the participating couples during PDE5 inhibitor therapy. AIM: To 
      determine to what extent patients personally informed their sexual partners about 
      their ongoing PDE5 inhibitor therapy. MAIN OUTCOME MEASURES: Likelihood of 
      informing the female partner by the patient himself about the use of PDE5 
      inhibitors. METHODS: A total of 216 men (mean age 62.3 years) with ED were 
      successfully treated with PDE5 inhibitors in three independent centers. After an 
      interval of at least 3 months of successful ED therapy, all patients were asked 
      by questionnaire whether their sexual partners were informed of their PDE5 
      inhibitor therapy. RESULTS: Eighty-two percent of the patients were exclusively 
      involved in one stable sexual relationship, 9.7% of the men admitted to having 
      changing sexual partners, and 6% did not give any information at all about their 
      sexual partners. Twenty percent of the men had a severe ED (International Index 
      of Erectile Function [IIEF-5] <11). Forty-nine percent showed a moderate ED 
      (IIEF-5 11-16) and 31% suffered a mild ED (IIEF-5 >16). PDE5 inhibitor medication 
      was used 1.2 times/month by men with a severe ED, 2.1 times/month by patients 
      with a moderate ED, and 2.9 times/month by men with a mild ED. Forty-one (93%) of 
      the 44 patients with a severe ED informed their sexual partners that they were 
      taking PDE5 inhibitors. In the patient group with moderate ED, 49 (47%) of 105 
      patients and only 14 (21%) of 67 of the patients with mild ED shared this 
      information with their partners. CONCLUSION: Less than 40% of the patients 
      suffering a moderate or mild ED using PDE5 inhibitors shared this information 
      with their partners. It seems that patients find ED so disturbing that many 
      patients do not inform their partners of PDE5 inhibitor use.
FAU - Klotz, Theodor
AU  - Klotz T
AD  - Department of Urology, Klinikum Weiden, Weiden, Germany;. Electronic address: 
      theodor.klotz@email.de.
FAU - Mathers, Mike
AU  - Mathers M
AD  - Urological Ambulatory, Remscheid, Germany.
FAU - Klotz, Rosemarie
AU  - Klotz R
AD  - Internal Medicine Ambulatory, Munich, Germany.
FAU - Sommer, Frank
AU  - Sommer F
AD  - Institute of Men's Health-Department of Urology, University of Hamburg, Hamburg, 
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20061106
PL  - Netherlands
TA  - J Sex Med
JT  - The journal of sexual medicine
JID - 101230693
RN  - 0 (Phosphodiesterase Inhibitors)
SB  - IM
MH  - Aged
MH  - Erectile Dysfunction/*drug therapy/psychology
MH  - Female
MH  - Humans
MH  - *Interpersonal Relations
MH  - Male
MH  - Middle Aged
MH  - *Patient Satisfaction
MH  - Phosphodiesterase Inhibitors/therapeutic use
MH  - Quality of Life
MH  - Severity of Illness Index
MH  - Sexual Partners/*psychology
MH  - Surveys and Questionnaires
MH  - Trust
EDAT- 2006/11/08 09:00
MHDA- 2007/03/22 09:00
CRDT- 2006/11/08 09:00
PHST- 2006/11/08 09:00 [pubmed]
PHST- 2007/03/22 09:00 [medline]
PHST- 2006/11/08 09:00 [entrez]
AID - S1743-6095(15)31502-2 [pii]
AID - 10.1111/j.1743-6109.2006.00346.x [doi]
PST - ppublish
SO  - J Sex Med. 2007 Jan;4(1):162-165. doi: 10.1111/j.1743-6109.2006.00346.x. Epub 
      2006 Nov 6.